EP0612249A4 - Methods of inhibiting restenosis. - Google Patents

Methods of inhibiting restenosis.

Info

Publication number
EP0612249A4
EP0612249A4 EP92924424A EP92924424A EP0612249A4 EP 0612249 A4 EP0612249 A4 EP 0612249A4 EP 92924424 A EP92924424 A EP 92924424A EP 92924424 A EP92924424 A EP 92924424A EP 0612249 A4 EP0612249 A4 EP 0612249A4
Authority
EP
European Patent Office
Prior art keywords
methods
inhibiting restenosis
restenosis
inhibiting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP92924424A
Other versions
EP0612249A1 (en
Inventor
Howard C Herrmann
Elliot Barnathan
Paul B Weisz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pennsylvania Penn
Original Assignee
University of Pennsylvania Penn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IL10002391A external-priority patent/IL100023A/en
Application filed by University of Pennsylvania Penn filed Critical University of Pennsylvania Penn
Publication of EP0612249A1 publication Critical patent/EP0612249A1/en
Publication of EP0612249A4 publication Critical patent/EP0612249A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
    • A61L15/28—Polysaccharides or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
    • A61L26/0023—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/20—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/28—Materials for coating prostheses
    • A61L27/34—Macromolecular materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
    • A61L27/3608—Bone, e.g. demineralised bone matrix [DBM], bone powder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
    • A61L33/0005—Use of materials characterised by their function or physical properties
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C07K14/503—Fibroblast growth factor [FGF] basic FGF [bFGF]
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/23—Carbohydrates
    • A61L2300/232—Monosaccharides, disaccharides, polysaccharides, lipopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412—Tissue-regenerating or healing or proliferative agents
    • A61L2300/414—Growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/80—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special chemical form
    • A61L2300/802—Additives, excipients, e.g. cyclodextrins, fatty acids, surfactants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Materials Engineering (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Nanotechnology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Botany (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Surgery (AREA)
  • Urology & Nephrology (AREA)
EP92924424A 1991-11-11 1992-11-10 Methods of inhibiting restenosis. Withdrawn EP0612249A4 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
IL100023 1991-11-11
IL10002391A IL100023A (en) 1991-11-11 1991-11-11 Pharmaceutical composition comprising a cyclodextrin derivative for the inhibition of undesired smooth muscle cell growth following angioplasty
US79032091A 1991-11-12 1991-11-12
US790320 1991-11-12
US90059292A 1992-06-18 1992-06-18
US900592 1992-06-18
PCT/US1992/009754 WO1993009790A1 (en) 1991-11-11 1992-11-10 Methods of inhibiting restenosis

Publications (2)

Publication Number Publication Date
EP0612249A1 EP0612249A1 (en) 1994-08-31
EP0612249A4 true EP0612249A4 (en) 1995-11-08

Family

ID=27271521

Family Applications (1)

Application Number Title Priority Date Filing Date
EP92924424A Withdrawn EP0612249A4 (en) 1991-11-11 1992-11-10 Methods of inhibiting restenosis.

Country Status (8)

Country Link
EP (1) EP0612249A4 (en)
JP (1) JPH07500843A (en)
AU (1) AU678760B2 (en)
BR (1) BR9206736A (en)
CA (1) CA2124857A1 (en)
FI (1) FI942166A (en)
NO (1) NO941738L (en)
WO (1) WO1993009790A1 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
EP0589578B1 (en) * 1992-09-24 1998-12-23 Terumo Kabushiki Kaisha Sulfonated compounds of beta-cyclodextrin polymer and inhibitory drug for vascular wall hyperplasia containing the same
ATE406909T1 (en) * 1993-05-13 2008-09-15 Poniard Pharmaceuticals Inc PREVENTION AND TREATMENT OF PATHOLOGIES ASSOCIATED WITH ABNORMAL PROLIFERATION OF SMOOTH MUSCLE CELLS
US5464815A (en) * 1993-09-08 1995-11-07 Genentech, Inc. Inhibition of heparin-binding
US5464827A (en) * 1994-06-20 1995-11-07 American Home Products Corporation Esterified polyanionic cyclodextrins as smooth muscle cell proliferation inhibitors
US5773420A (en) * 1994-11-07 1998-06-30 American Home Products Corporation Acylated benzylglycosides as inhibitors of smooth muscle cell proliferation
US5498775A (en) * 1994-11-07 1996-03-12 American Home Products Corporation Polyanionic benzylglycosides as inhibitors of smooth muscle cell proliferation
US5565432A (en) * 1994-11-07 1996-10-15 American Home Products Corporation Smooth muscle cell proliferation inhibitors
WO1997039761A1 (en) * 1996-04-19 1997-10-30 Alpha Therapeutic Corporation A process for viral inactivation of lyophilized blood proteins
AUPO888497A0 (en) 1997-09-01 1997-09-25 Australian National University, The Use of sulfated oligosaccharides as inhibitors of cardiovascular disease
IL125336A0 (en) * 1998-07-14 1999-03-12 Yissum Res Dev Co Compositions for inhibition and treatment of restinosis
US6664243B1 (en) 1998-11-24 2003-12-16 Wyeth Benzyllactobionamides as inhibitors of smooth muscle cell proliferation
US6339064B1 (en) 1998-11-24 2002-01-15 American Home Products Corporation Benzylglycosylamides as inhibitors of smooth muscle cell proliferation
US6362170B1 (en) 1998-11-24 2002-03-26 American Home Products Corporation Benzylglycosylamides as inhibitors of smooth muscle cell proliferation
US6291434B1 (en) 1998-11-24 2001-09-18 American Home Products Corp. Benzylmaltotriosides as inhibitors of smooth muscle cell proliferation
US7132402B2 (en) 1998-11-24 2006-11-07 Wyeth Acylated benzylmaltosides as inhibitors of smooth muscle cell proliferation
US7081448B2 (en) 1998-11-24 2006-07-25 Wyeth Benzyllactobionamides as inhibitors of smooth muscle cell proliferation
US6187755B1 (en) 1998-11-24 2001-02-13 American Home Products Corporation Benzylmaltosides as inhibitors of smooth muscle cell proliferation
US6258784B1 (en) 1998-11-24 2001-07-10 American Home Products Corp. Acetal benzylmaltosides as inhibitors of smooth muscle cell proliferation
US6451767B1 (en) 1998-11-24 2002-09-17 Wyeth Benzylmaltotriosides as inhibitors of smooth muscle cell proliferation
US6340670B1 (en) 1998-11-24 2002-01-22 American Home Products Corporation Acetal benzylmaltosides as inhibitors of smooth muscle cell proliferation
FR2811572B1 (en) 2000-07-17 2003-04-18 Adir USE OF POLYSULFATED CYCLODEXTRINS FOR THE TREATMENT OF ARTHROSIS
FR2827799A1 (en) * 2001-07-27 2003-01-31 Sofradim Production Coating metal substrates with polysaccharide, e.g. for production of vascular endoprostheses, involves chemical modification, application of a reactive silane as coupling agent and coating with polysaccharide solution
US10517883B2 (en) 2003-06-27 2019-12-31 Zuli Holdings Ltd. Method of treating acute myocardial infarction
FR2923391B1 (en) * 2007-11-08 2012-07-27 Biocydex COMPOSITIONS FOR PRESERVING CELLS, TISSUES OR ORGANS, METHOD OF OBTAINING AND USES.
WO2010031876A1 (en) * 2008-09-22 2010-03-25 Universiteit Gent Carboxyethylated cyclodextrin polysulfates useful as medicaments
US9993427B2 (en) 2013-03-14 2018-06-12 Biorest Ltd. Liposome formulation and manufacture

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0345660A1 (en) * 1988-06-06 1989-12-13 Takeda Chemical Industries, Ltd. Stabilized FGF composition and production thereof
WO1990002133A1 (en) * 1988-08-25 1990-03-08 Formulations Development Laboratories, Inc. Method for preparing sucralfate and aai-10001
EP0550035A2 (en) * 1991-12-26 1993-07-07 Kaken Pharmaceutical Co., Ltd. Composition of stabilized fibroblast growth factor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4020160A (en) * 1975-08-15 1977-04-26 American Cyanamid Company Cyclodextrin sulfate salts as complement inhibitors
EP0299975B1 (en) * 1986-04-04 1992-11-11 Angiogenics Limited Composition for arresting angiogenesis and capillary, cell or membrane leakage
ES2059571T3 (en) * 1988-01-19 1994-11-16 Takeda Chemical Industries Ltd FUMAGILINA AS AN ANGIOSTATIC AGENT.
US5019562A (en) * 1988-01-19 1991-05-28 The Trustees Of The University Of Pennsylvania/Childrens Hospital Corporation Growth inhibiting agent and the use thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0345660A1 (en) * 1988-06-06 1989-12-13 Takeda Chemical Industries, Ltd. Stabilized FGF composition and production thereof
WO1990002133A1 (en) * 1988-08-25 1990-03-08 Formulations Development Laboratories, Inc. Method for preparing sucralfate and aai-10001
EP0550035A2 (en) * 1991-12-26 1993-07-07 Kaken Pharmaceutical Co., Ltd. Composition of stabilized fibroblast growth factor

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO9309790A1 *

Also Published As

Publication number Publication date
NO941738D0 (en) 1994-05-10
JPH07500843A (en) 1995-01-26
FI942166A0 (en) 1994-05-10
WO1993009790A1 (en) 1993-05-27
FI942166A (en) 1994-07-08
AU3074292A (en) 1993-06-15
AU678760B2 (en) 1997-06-12
BR9206736A (en) 1995-10-31
EP0612249A1 (en) 1994-08-31
CA2124857A1 (en) 1993-05-27
NO941738L (en) 1994-07-11

Similar Documents

Publication Publication Date Title
EP0612249A4 (en) Methods of inhibiting restenosis.
HU9203545D0 (en) Anti-thrombotic preparatives
SG46381A1 (en) Leukoriene biiosynthese inhibitor
ZA934603B (en) thiazolylvinylphenyl derivatives.
EP0601322A3 (en) Adenosindeaminase inhibitor.
GB2252320B (en) Nitrosamine inhibition
DE59204008D1 (en) Trachealstent.
ZA926482B (en) Cyanophenylpyrroles.
GB2257256B (en) Plastometer
ZA927792B (en) Anti-alpha6-integrin-antibodies.
PH31326A (en) Methods of inhibiting breast disorders.
GB9024470D0 (en) Corrision inhibition
OA09716A (en) Benzoxaiole derivatives.
GB9021261D0 (en) Scale inhibition
ZA929590B (en) Diphenylsulphides.
ZA928427B (en) The formation of an element for an article of jewellery.
DE69205795D1 (en) Mesoprotheseunterlage.
DE69203865D1 (en) Thermo-transferdrucksystem.
DE69204801D1 (en) Hydroxy- oder oxosubstituierte alkylcyclopentene.
ZA929331B (en) Quinolylmethoxyphenyl-acetamides.
ZA925725B (en) Qinolin-2-yl-methoxybenzylhydroxyureas.
ZA929820B (en) Heisswinderschieber.
ZA921865B (en) Isoxazole- and isothiazole-5-carboxamides.
GB9112528D0 (en) Anti-corrosion treatment
GB9108786D0 (en) Effluent treatment

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19940530

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL SE

A4 Supplementary search report drawn up and despatched

Effective date: 19950921

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL SE

17Q First examination report despatched

Effective date: 19971030

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19990826